Cell-based assay services incorporating Horizon’s
isogenic cell line technology
Through Ubiquigent’s relationship with Horizon and access to their cell line technology platforms we are delighted to offer a range of service capabilities to assist you in your ubiquitin system basic and drug discovery applied research including:
- pathway validation
- target discovery and validation
- compound mechanism of action validation
- biomarker discovery and validation
Access to genetically defined isogenic cell lines including knock-outs, knock-ins and site directed mutations
Ubiquigent has access to Horizon’s comprehensive array of ubiquitin system knock out genetically defined and highly validated human cell lines for application in our ubiquitin system research and drug discovery services (learn more about Horizon cell lines here and click here for a full listing of cell lines available as part of Ubiquigent’s drug discovery services). For optimal experimental control, the isogenic control (wild type) cell line is also available with each modified/mutant cell line selected. Furthermore if the cell line that you need is not listed then through our relationship with Horizon we can have customised lines generated to provide you with the precise assay service that you require. By way of example such customised cell lines may carry active site directed mutations or tags on specific ubiquitin system or ubiquitin system target (substrate) proteins or reporters linked to ubiquitin system gene promoters.
The Horizon proprietary HAP1 cell line is derived from the male chronic myelogenous leukaemia (CML) cell line KBM-7. Click here for further information about the HAP1 cell line.
Please click here for a list of publications referencing the application of Horizon’s HAP1 cell lines.